Insmed Inc (INSM)vsPhathom Pharmaceuticals Inc (PHAT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PHAT
Phathom Pharmaceuticals Inc
$10.47
+4.08%
HEALTHCARE · Cap: $883.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 246% more annual revenue ($606.42M vs $175.11M). INSM leads profitability with a -2.1% profit margin vs -126.4%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PHAT
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 94.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -34.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PHAT
The strongest argument for PHAT centers on Revenue Growth, Debt/Equity. Revenue growth of 94.1% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PHAT
The primary concerns for PHAT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PHAT is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
PHAT is growing revenue faster at 94.1% — sustainability is the question.
PHAT generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Phathom Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?